Understanding the molecular pathogenesis of primary central nervous system lymphoma by experimental animal models
Journal of Cellular Physiology · 2023
DOI: 10.1002/jcp.31107 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular Physiology, 2023. Verfasst von Di Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medicine, School of Medicine, Foshan University, Foshan, Guangdong, China. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Natural Science Foundation of Guangdong Province of China, The Key Projects of Department of Education of Guangdong Province of China.
Abstract (Originalsprache)
Primary central nervous system lymphoma (PCNSL) is a rare and invasive diffuse large B cell lymphoma confined in central nervous system (CNS). The effort to press forward the translational progress has been frustrated by the insufficient understanding of immunophenotype of CNS and tumor genetic alterations of PCNSL, and the lack of validated diagnostic biomarkers. Researchers now have a variety of PCNSL animal models at their disposal that resemble the morphology and immunophenotype of PCNSL, however, a careful and detailed re‐examination of these animal models is needed to clarify the differences in genetic alterations, migration capability, and immune status. In this review, we present the knowledge about the phenotypic and genotypic features of PCNSL tumor cells, and compile the preclinical animal models of PCNSL with regard to various injection sites, cell origins, recipient animals, and immune status, and elaborate on the tropism and migration of tumor cells and novel therapeutic strategies for PCNSL. We envisage that the selection of suitable animal models will serve as a well‐defined preclinical system to understand the molecular pathogenesis of PCNSL, thereby galvanizing the development of novel and potent therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Basic Medicine, School of Medicine, Foshan University, Foshan, Guangdong, China.
- Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
- Department of Pulmonary and Critical Care Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
- State Key Laboratory of Oncology in South China, Department of Neurosurgery and Neuro-oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
- Laboratory for Excellence in Systems Biomedicine of Pediatric Oncology, Department of Pediatric Hematology and Oncology, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development…
ORCID-Profile: Hua You
Förderung
- National Natural Science Foundation of China
- The Natural Science Foundation of Guangdong Province of China
- The Key Projects of Department of Education of Guangdong Province of China
- Guangdong Basic and Applied Basic Research Foundation
- CQMU Program for Youth Innovation in Future Medicine
- Talent Program of Chongqing Health Commission
Zitieren
APA
Wu, D., Liu, D., Tateishi, K., Qi, F., Yang, F., Ke, C., & You, H. (2023). Understanding the molecular pathogenesis of primary central nervous system lymphoma by experimental animal models. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.31107
Vancouver
Wu D, Liu D, Tateishi K, Qi F, Yang F, Ke C, et al. Understanding the molecular pathogenesis of primary central nervous system lymphoma by experimental animal models. Journal of Cellular Physiology. 2023. doi:10.1002/jcp.31107
BibTeX
@article{Wu2023,
author = {Wu, Di and Liu, Dahai and Tateishi, Kensuke and Qi, Fei and Yang, Fang and Ke, Chao and You, Hua},
title = {Understanding the molecular pathogenesis of primary central nervous system lymphoma by experimental animal models},
journal = {Journal of Cellular Physiology},
year = {2023},
doi = {10.1002/jcp.31107}
}
EUVIMED